{"entity":{"id":"caps-consortium-pancreatic-screening","kind":"term","name":"CAPS: the Cancer of the Pancreas Screening consortium and its surveillance studies (CAPS1 to CAPS5)","aka":["CAPS consortium","CAPS1","CAPS2","CAPS3","CAPS4","CAPS5","International Cancer of the Pancreas Screening Consortium","Cancer of Pancreas Screening study"],"tldr":"CAPS is the Johns Hopkins-led programme that has followed people at high inherited risk of pancreatic cancer with yearly endoscopic ultrasound and MRI since the late 1990s, and the consortium whose consensus statements set who should be watched and how. Its cohorts are the evidence that surveillance finds most cancers at stage I.","summary":"The CAPS studies enrolled people with a strong family history or a known predisposition gene: in the long-term Johns Hopkins cohort of 354 high-risk individuals followed over 16 years, 7% progressed to high-grade dysplasia or cancer (about 1.6% a year), 93% had worrisome features first and 9 of 10 surveillance-detected cancers were resectable (Canto 2018). Across CAPS1 to CAPS5 (1,731 people; 1,461 in CAPS5 alone), 57.9% of the 19 cancers found under surveillance were stage I against 85.7% stage IV for the seven found outside it, with five-year survival 73.3% and median overall survival 9.8 years against 1.5 years (Dbouk 2022); 7 of 9 CAPS5 cancers were stage I. The International CAPS Consortium's 2020 consensus set the goal as high-grade dysplasia and T1N0M0 cancer, starts familial surveillance at 50 or 55 or ten years before the youngest affected relative, uses endoscopic ultrasound and MRI/MRCP yearly and admitted ATM carriers with one affected first-degree relative (Goggins 2020). NICE NG85's surveillance criteria and the UK EUROPAC registry follow the same logic; PRECEDE is building the international cohort that succeeds it.","asOf":"2026-09-24","links":[{"label":"Canto et al., Gastroenterology 2018: 16 years of CAPS surveillance in 354 high-risk individuals","url":"https://doi.org/10.1053/j.gastro.2018.05.035"},{"label":"Dbouk et al., J Clin Oncol 2022: CAPS5, stage and survival in 1,461 high-risk individuals","url":"https://doi.org/10.1200/JCO.22.00298"},{"label":"Goggins et al., Gut 2020: CAPS consortium updated recommendations","url":"https://doi.org/10.1136/gutjnl-2019-319352"}],"tags":["pancreatic-molecular"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["pancreatic-surveillance","endoscopic-ultrasound-systems","mri","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":["familial-pancreatic-cancer","pancreatic-cyst-high-risk-stigmata","hereditary-cancer-syndromes","stage-shift"],"trials":["precede","europac"],"people":[],"bottlenecks":[],"keyPapers":["paper-canto-caps-long-term-surveillance-gastroenterology-2018","paper-dbouk-caps5-stage-survival-jco-2022","paper-caps-consortium-surveillance-recommendations-gut-2020"],"journals":[],"dependsOn":[],"notes":[],"category":"Epidemiology & prevention"},"route":"/terms/caps-consortium-pancreatic-screening/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"endoscopic-ultrasound-systems","kind":"technology","name":"Endoscopic ultrasound and EBUS systems","route":"/technologies/endoscopic-ultrasound-systems/"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/"},{"id":"pancreatic-surveillance","kind":"technology","name":"High-risk pancreatic surveillance (CAPS / PRECEDE)","route":"/technologies/pancreatic-surveillance/"},{"id":"mri","kind":"technology","name":"MRI","route":"/technologies/mri/"}],"institution":[{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/"}],"term":[{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/"},{"id":"hereditary-cancer-syndromes","kind":"term","name":"Hereditary cancer syndromes","route":"/terms/hereditary-cancer-syndromes/"},{"id":"pancreatic-cyst-high-risk-stigmata","kind":"term","name":"High-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria)","route":"/terms/pancreatic-cyst-high-risk-stigmata/"},{"id":"stage-shift","kind":"term","name":"Stage shift","route":"/terms/stage-shift/"}],"trial":[{"id":"europac","kind":"trial","name":"EUROPAC","route":"/trials/europac/"},{"id":"precede","kind":"trial","name":"PRECEDE","route":"/trials/precede/"}],"paper":[{"id":"paper-caps-consortium-surveillance-recommendations-gut-2020","kind":"paper","name":"Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium","route":"/key-papers/paper-caps-consortium-surveillance-recommendations-gut-2020/"},{"id":"paper-canto-caps-long-term-surveillance-gastroenterology-2018","kind":"paper","name":"Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance","route":"/key-papers/paper-canto-caps-long-term-surveillance-gastroenterology-2018/"},{"id":"paper-dbouk-caps5-stage-survival-jco-2022","kind":"paper","name":"The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival","route":"/key-papers/paper-dbouk-caps5-stage-survival-jco-2022/"}]}}